Skip to main content
West Pharmaceutical Services8-K: Material contract

WST renews 10-year technology exchange and exclusive distribution agreements with partner Daikyo Seiko

What happened

This renewal solidifies West Pharmaceutical's long-term R&D pipeline and exclusive international distribution rights for Daikyo's pharmaceutical packaging products. This deepens their strategic focus on joint development, potentially creating needs for collaborative R&D tools or advanced supply chain management systems to support the decade-long partnership.

Source

SEC EDGARJul 14, 2026

Current report (Form 8-K)

West Pharmaceutical Services 8-K

Filing excerpt

West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship Agreements (the “Distributorship Agreements”) effective July 14, 2026 (the “Agreements”).

sec.gov/Archives/edgar/data/105770/000010577026000093/wst-20260714.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
8-K: Material contract

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
07/14
Filed
Jul 14, 2026

The full record

From the Signal API record

Numbers

Percent
49% (Company's ownership interest in partner Daikyo Seiko, Ltd.)

Details

CIK
105770
Accession number
0000105770-26-000093
Filing year
2026
Why it matters
Vendor relationship signal
Signal category
Strategic

Topics and mentions

Regions named

  • Japan

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Jul 21, 2026
signal_type
sec-8k
signal_subtype
materialContract

Use this data

Get every 8-K signal for West Pharmaceutical Services and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at West Pharmaceutical Services this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/03675534-7e88-46bc-8bfd-7fd9ec29d837 returns this record as JSON. POST /v1/companies/enrich returns every signal for westpharma.com.

{
  "signal_id": "03675534-7e88-46bc-8bfd-7fd9ec29d837",
  "signal_type": "sec-8k",
  "signal_subtype": "materialContract",
  "detected_at": "2026-07-21T07:04:29.439+00:00",
  "company": {
    "name": "West Pharmaceutical Services",
    "domain": "westpharma.com"
  },
  "data": {
    "detail": "This renewal solidifies West Pharmaceutical's long-term R&D pipeline and exclusive international distribution rights for Daikyo's pharmaceutical packaging products. This deepens their strategic focus on joint development, potentially creating needs for collaborative R&D tools or advanced supply chain management systems to support the decade-long partnership.",
    "metrics": {
      "pct": 0.49,
      "pct_context": "Company's ownership interest in partner Daikyo Seiko, Ltd."
    },
    "summary": "WST renews 10-year technology exchange and exclusive distribution agreements with partner Daikyo Seiko",
    "excerpts": "West Pharmaceutical Services, Inc. (the \"Company\") and Daikyo Seiko, Ltd. (\"Daikyo\") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship Agreements (the “Distributorship Agreements”) effective July 14, 2026 (the “Agreements”).",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/wst-20260714.htm",
    "filing_date": "2026-07-14",
    "filing_year": 2026,
    "fiscal_year_end": "07/14",
    "sales_relevance": "Vendor relationship signal",
    "signal_category": "strategic",
    "regions_mentioned": [
      "Japan"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.